S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
NASDAQ:TLIS

Talis Biomedical (TLIS) Stock Price, News & Analysis

$8.97
+0.09 (+1.01%)
(As of 09:38 AM ET)
Today's Range
$8.75
$8.97
50-Day Range
$7.20
$9.25
52-Week Range
$4.35
$9.32
Volume
2,808 shs
Average Volume
8,574 shs
Market Capitalization
$16.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Talis Biomedical MarketRank™ Stock Analysis

Analyst Rating
Sell
1.00 Rating Score
Upside/​Downside
44.3% Downside
$5.00 Price Target
Short Interest
Healthy
0.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Talis Biomedical in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.34 out of 5 stars

Medical Sector

926th out of 939 stocks

Medical Devices Industry

2nd out of 2 stocks

TLIS stock logo

About Talis Biomedical Stock (NASDAQ:TLIS)

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B. The company was incorporated in 2013 and is headquartered in Redwood, California.

TLIS Stock Price History

TLIS Stock News Headlines

Talis Biomedical (NASDAQ:TLIS) Trading Down 2.2%
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
TLIS Feb 2024 2.500 put
LICY, BTAI and HROW among mid-day movers
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
A Preview Of Talis Biomedical's Earnings
TLIS - Talis Biomedical Corporation
Talis Biomedical reports Q1 results
See More Headlines
Receive TLIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/15/2022
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
NASDAQ:TLIS
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
-44.3%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$-113,010,000.00
Net Margins
-3,436.98%
Pretax Margin
-3,436.98%

Debt

Sales & Book Value

Annual Sales
$4.81 million
Book Value
$70.95 per share

Miscellaneous

Free Float
983,000
Market Cap
$16.33 million
Optionable
No Data
Beta
1.71
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Robert Kelley MBA (Age 52)
    CEO & Director
    Comp: $1.05M
  • Dr. Rustem F. Ismagilov Ph.D. (Age 50)
    Co-Founder & Director
    Comp: $75.36k
  • Dr. Andrew A. Lukowiak Ph.D. (Age 52)
    President & Chief Scientific Officer
  • Mr. Liang Li Ph.D.
    Co-Founder and Director of Technology & Strategy
  • Ms. Rebecca Markovich (Age 51)
    Interim Chief Financial Officer
  • Ms. Emily Faucette
    Senior Vice President of Corporate Communications & Investor Relations
  • Ms. Jill Green
    Senior Vice President of Legal
  • Mr. Matthew Pepe
    Vice President of Human Resource
  • Ms. Margaret Barrett M.S.
    Controller
  • Gillian Green
    Company Secretary

TLIS Stock Analysis - Frequently Asked Questions

Should I buy or sell Talis Biomedical stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Talis Biomedical in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" TLIS shares.
View TLIS analyst ratings
or view top-rated stocks.

What is Talis Biomedical's stock price target for 2024?

1 Wall Street analysts have issued 12 month target prices for Talis Biomedical's stock. Their TLIS share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next year. This suggests that the stock has a possible downside of 44.3%.
View analysts price targets for TLIS
or view top-rated stocks among Wall Street analysts.

How have TLIS shares performed in 2024?

Talis Biomedical's stock was trading at $7.45 at the start of the year. Since then, TLIS stock has increased by 20.4% and is now trading at $8.97.
View the best growth stocks for 2024 here
.

How were Talis Biomedical's earnings last quarter?

Talis Biomedical Co. (NASDAQ:TLIS) issued its quarterly earnings data on Tuesday, March, 15th. The company reported ($18.90) earnings per share for the quarter, topping analysts' consensus estimates of ($19.20) by $0.30. Talis Biomedical had a negative net margin of 3,436.98% and a negative trailing twelve-month return on equity of 72.82%.

When did Talis Biomedical's stock split?

Talis Biomedical shares reverse split on Thursday, July 6th 2023. The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Talis Biomedical IPO?

Talis Biomedical (TLIS) raised $150 million in an initial public offering on Friday, February 12th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager.

Who are Talis Biomedical's major shareholders?

Talis Biomedical's stock is owned by a number of institutional and retail investors. Top institutional investors include BML Capital Management LLC (2.35%), Citadel Advisors LLC (0.55%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bros Advisors Lp Baker and Randal W Scott.
View institutional ownership trends
.

How do I buy shares of Talis Biomedical?

Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TLIS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners